Spiriva Approval History
- FDA approved: Yes (First approved January 30th, 2004)
- Brand name: Spiriva
- Generic name: tiotropium bromide
- Dosage form: Inhalation Powder
- Company: Boehringer Ingelheim
- Treatment for: COPD, Maintenance
Spiriva HandiHaler (tiotropium bromide) is an anticholinergic indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), and for reducing COPD exacerbations.
Development History and FDA Approval Process for Spiriva
|Dec 18, 2009||FDA Approves Spiriva HandiHaler for the Reduction of COPD Exacerbations|
|Jan 30, 2004||Spiriva HandiHaler Boehringer Ingelheim - Treatment for Chronic Obstructive Pulmonary Disease (COPD)|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.